Clark J - Search Results

1

Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials.

Atkins MB, Dutcher J, Weiss G, Margolin K, Clark J, Sosman J, Logan T, Aronson F, Mier J; Cytokine Working Group. Atkins MB, et al. Among authors: clark j. Med Oncol. 2001;18(3):197-207. doi: 10.1385/MO:18:3:197. Med Oncol. 2001. PMID: 11917944 Review.

2

Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma.

Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Stadler WM, et al. Among authors: clark j. J Clin Oncol. 1999 Aug;17(8):2541-5. doi: 10.1200/JCO.1999.17.8.2541. J Clin Oncol. 1999. PMID: 10561320 Clinical Trial.

3

Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.

Dutcher JP, Logan T, Gordon M, Sosman J, Weiss G, Margolin K, Plasse T, Mier J, Lotze M, Clark J, Atkins M. Dutcher JP, et al. Among authors: clark j. Clin Cancer Res. 2000 Sep;6(9):3442-50. Clin Cancer Res. 2000. PMID: 10999727 Clinical Trial.

4

Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines.

Dutcher J, Atkins MB, Margolin K, Weiss G, Clark J, Sosman J, Logan T, Aronson F, Mier J; Cytokine Working Group. Dutcher J, et al. Among authors: clark j. Med Oncol. 2001;18(3):209-19. doi: 10.1385/MO:18:3:209. Med Oncol. 2001. PMID: 11917945 Review.

5

Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies.

Herman TS, Teicher BA, Jochelson M, Clark J, Svensson G, Coleman CN. Herman TS, et al. Among authors: clark j. Int J Hyperthermia. 1988 Mar-Apr;4(2):143-58. doi: 10.3109/02656738809029305. Int J Hyperthermia. 1988. PMID: 3283266 Free article. Review.

6

Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.

Buswell L, Recht A, Clark J, Ravikumar T, Busse PM, Coleman CN. Buswell L, et al. Among authors: clark j. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):535-40. doi: 10.1016/0360-3016(94)90451-0. Int J Radiat Oncol Biol Phys. 1994. PMID: 8005812 Clinical Trial.

7

Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.

Bunnell CA, Supko JG, Eder JP Jr, Clark JW, Lynch TJ, Kufe DW, Shulman LN. Bunnell CA, et al. Among authors: clark jw. Cancer Chemother Pharmacol. 2001 Nov;48(5):347-55. doi: 10.1007/s002800100319. Cancer Chemother Pharmacol. 2001. PMID: 11761451 Clinical Trial.

8

Phase II study of paclitaxel and carboplatin for malignant melanoma.

Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Hodi FS, et al. Among authors: clark j. Am J Clin Oncol. 2002 Jun;25(3):283-6. doi: 10.1097/00000421-200206000-00016. Am J Clin Oncol. 2002. PMID: 12040289 Clinical Trial.

9

Using "rationally designed drugs" rationally.

Brugarolas J, Clark JW, Chabner B. Brugarolas J, et al. Among authors: clark jw. Lancet. 2003 May 24;361(9371):1758-9. doi: 10.1016/S0140-6736(03)13446-0. Lancet. 2003. PMID: 12781531 No abstract available.

10

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

Roberts TG Jr, Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, Gazelle GS, Finkelstein SN, Clark JW. Roberts TG Jr, et al. JAMA. 2004 Nov 3;292(17):2130-40. doi: 10.1001/jama.292.17.2130. JAMA. 2004. PMID: 15523074

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,571 results

Search Page

Filters